Isoniazid (INH) remains a cornerstone of first-line therapy for tuberculosis, yet resistance to this drug poses a major obstacle to global control efforts. Isoniazid is a prodrug that requires ...
Mycobacterium tuberculosis has evolved a diverse array of resistance mechanisms that undermine the efficacy of first- and second-line antitubercular agents. Central to this adaptability are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results